The road to treating smoldering multiple myeloma

Neha Korde, Sham Mailankody, Ola Landgren

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

The management of smoldering multiple myeloma (SMM) has been a challenge to clinicians, ever since the condition was first characterized in 1980. While the risk of progression to symptomatic myeloma is greater for SMM (10% per year) compared to MGUS (1% per year), several SMM patients remain asymptomatic for years without evidence of disease progression. Early clinical trials focusing on early treatment of SMM have been equivocal with no clear benefit. However, the last decade has seen a greater understanding of the pathogenesis of plasma cell disorders, including SMM, and development of better therapeutics. A recent randomized trial has provided evidence of clinical benefit with early treatment of high-risk SMM. In this review, we summarize issues related to the early treatment of SMM including risk stratification and possible outcomes with therapy initiation. In the context of reviewing recent clinical trial data supporting early treatment, we define challenges faced by clinicians and provide future directions to the road to treating SMM.

Original languageEnglish (US)
Pages (from-to)S59-S64
JournalClinical Lymphoma, Myeloma and Leukemia
Volume14
DOIs
StatePublished - Sep 1 2014
Externally publishedYes

Keywords

  • High-risk SMM
  • MGUS
  • Minimal residual disease
  • Monoclonal protein
  • Plasma cells

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'The road to treating smoldering multiple myeloma'. Together they form a unique fingerprint.

Cite this